Touch of flu
Article Abstract:
Glaxo Wellcome has produced a flu remedy, Relenza, and the United Kingdom National Institute for Clinical Excellence has not recommended that Relenza be used by the National Health Service (NHS). The government may decide that Relenza will not be reimbursed, as a result of this advice. Relenza is expected to have the US as its mainmarket, and it can still be bought in the UK. Glaxo argues that assessments of the cost-effectiveness of the drug cannot be made until it has been widely used.
Publication Name: The Economist (UK)
Subject: Business, international
ISSN: 0013-0613
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Protection racket
Article Abstract:
Issues related to drug patents are examined in detail. Ways that pharmaceutical companies seek to develop their patents are also assessed, with examples.
Publication Name: The Economist (UK)
Subject: Business, international
ISSN: 0013-0613
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
Drug-induced dilemma
Article Abstract:
The policies of drug companies toward South Africa are examined, including patent issues.
Publication Name: The Economist (UK)
Subject: Business, international
ISSN: 0013-0613
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: i-modest success. Lost in space. Built on thin air: wireless telephony
- Abstracts: ProjectBank. Hitting the jackpot. MicroGDS
- Abstracts: The art of bug hunting. Hackers rule
- Abstracts: A cafe with a view. Tonkin's touch of the Orient. Light lunch
- Abstracts: Demers to boost Quebec content. Remembering Jacques. As the agency turns